Literature DB >> 26025561

Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy.

Zachary A Cooper1, Alexandre Reuben2, Jacob Austin-Breneman2, Jennifer A Wargo3.   

Abstract

BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26025561      PMCID： PMC4506225          DOI： 10.1158/1078-0432.CCR-15-0363

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Hepatotoxicity with combination of vemurafenib and ipilimumab.

Authors:  Antoni Ribas; F Stephen Hodi; Margaret Callahan; Cyril Konto; Jedd Wolchok
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.

Authors:  Li Liu; Patrick A Mayes; Stephen Eastman; Hong Shi; Sapna Yadavilli; Tianqian Zhang; Jingsong Yang; Laura Seestaller-Wehr; Shu-Yun Zhang; Chris Hopson; Lyuben Tsvetkov; Junping Jing; Shu Zhang; James Smothers; Axel Hoos
Journal:  Clin Cancer Res       Date:  2015-01-14       Impact factor: 12.531

4.  Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.

Authors:  Taha Merghoub; Maria Jure-Kunkel; Jedd D Wolchok; Margaret K Callahan; Gregg Masters; Christine A Pratilas; Charlotte Ariyan; Jessica Katz; Shigehisa Kitano; Valerie Russell; Ruth Ann Gordon; Shachi Vyas; Jianda Yuan; Ashok Gupta; Jon M Wigginton; Neal Rosen
Journal:  Cancer Immunol Res       Date:  2014-01       Impact factor: 11.151

5.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

6.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

7.  PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

Authors:  Hojabr Kakavand; James S Wilmott; Alexander M Menzies; Ricardo Vilain; Lauren E Haydu; Jennifer H Yearley; John F Thompson; Richard F Kefford; Peter Hersey; Georgina V Long; Richard A Scolyer
Journal:  Clin Cancer Res       Date:  2015-01-21       Impact factor: 12.531

8.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors:  Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544

9.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

10.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Authors:  Ronald P Dematteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar
Journal:  Lancet       Date:  2009-03-18       Impact factor: 79.321
View more
  12 in total

1.  Raising the bar: optimizing combinations of targeted therapy and immunotherapy.

Authors:  Alexandre Reuben; Jacob Austin-Breneman; Jennifer A Wargo; Zachary A Cooper
Journal:  Ann Transl Med       Date:  2015-10

Review 2.  Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.

Authors:  Mario Mandalà; Francesco De Logu; Barbara Merelli; Romina Nassini; Daniela Massi
Journal:  Lab Invest       Date:  2016-12-19       Impact factor: 5.662

Review 3.  The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.

Authors:  Kim Margolin
Journal:  Curr Treat Options Oncol       Date:  2016-09

Review 4.  Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.

Authors:  Zhong-Yi Dong; Si-Pei Wu; Ri-Qiang Liao; Shu-Mei Huang; Yi-Long Wu
Journal:  Tumour Biol       Date:  2016-01-16

Review 5.  Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis.

Authors:  Omar Abdel-Rahman; Hesham ElHalawani; Hoda Ahmed
Journal:  J Glob Oncol       Date:  2015-11-25

Review 6.  Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date.

Authors:  Amélie Boespflug; Julie Caramel; Stephane Dalle; Luc Thomas
Journal:  Ther Adv Med Oncol       Date:  2017-05-29       Impact factor: 8.168

7.  Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.

Authors:  Sathana Dushyanthen; Zhi Ling Teo; Franco Caramia; Peter Savas; Christopher P Mintoff; Balaji Virassamy; Melissa A Henderson; Stephen J Luen; Mariam Mansour; Michael H Kershaw; Joseph A Trapani; Paul J Neeson; Roberto Salgado; Grant A McArthur; Justin M Balko; Paul A Beavis; Phillip K Darcy; Sherene Loi
Journal:  Nat Commun       Date:  2017-09-19       Impact factor: 14.919

8.  Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.

Authors:  Dan A Erkes; Weijia Cai; Ileine M Sanchez; Timothy J Purwin; Corey Rogers; Conroy O Field; Adam C Berger; Edward J Hartsough; Ulrich Rodeck; Emad S Alnemri; Andrew E Aplin
Journal:  Cancer Discov       Date:  2019-12-03       Impact factor: 38.272

9.  BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.

Authors:  Jan Dörrie; Lek Babalija; Stefanie Hoyer; Kerstin F Gerer; Gerold Schuler; Lucie Heinzerling; Niels Schaft
Journal:  Int J Mol Sci       Date:  2018-01-18       Impact factor: 5.923

Review 10.  Current status and perspectives in immunotherapy for metastatic melanoma.

Authors:  Riccardo Marconcini; Francesco Spagnolo; Luigia Stefania Stucci; Simone Ribero; Elena Marra; Francesco De Rosa; Virginia Picasso; Lorenza Di Guardo; Carolina Cimminiello; Stefano Cavalieri; Laura Orgiano; Enrica Tanda; Laura Spano; Alfredo Falcone; Paola Queirolo
Journal:  Oncotarget       Date:  2018-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.